Insulin aspart

From Wikipedia, the free encyclopedia

Insulin aspart
Systematic (IUPAC) name
?
Identifiers
CAS number	116094-23-6
ATC code	A10AB05
PubChem	16132418
Chemical data
Formula	C256H387N65O79S6
Mol. mass	5831.6 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	℞-only(US)
Routes	Subcutaneous

Insulin aspart (marketed by Novo Nordisk as "NovoLog/NovoRapid") is a fast acting insulin analogue. It was created through recombinant DNA technology so that the amino acid, B28, which is normally proline, is substituted with an aspartic acid residue. This analogue has increased charge repulsion, which prevents the formation of hexamers, to create a faster acting insulin. The sequence was inserted into the yeast genome, and the yeast expressed the insulin analogue, which was then harvested from a bioreactor. Can be used in CSII pumps and Flexpen, Novopen delivery devices for subcutaneous injection. ^[1]

According to JDRF, insulin aspart was approved for marketing in the United States by the Food and Drug Administration in June of 2000.

It has been debated whether or not insulin aspart (or NovoLog/NovoRapid) should be refrigerated. Recent studies have shown that there is no difference, however insulin should not be stored in intense heat for a long period of time. This causes the hormone to reach a pre- boiling state, and separate. This can change the potency of the insulin, and it would no longer be as effective. A good rule of thumb is to keep the insulin at around room temperature or less.

[edit] References

1. ^ Aspart insulin (rDNA origin) injection. Retrieved on 2007-06-08.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10) Biguanides Metformin Sulfonylureas Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide Alpha-glucosidase inhibitors Acarbose, Miglitol, Voglibose Thiazolidinediones (TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ Meglitinides Nateglinide, Repaglinide, Mitiglinide Dipeptidyl peptidase-4 (DPP-4) inhibitors Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin Glucagon-like peptide-1 analog Exenatide, Liraglutide†, Albiglutide† Amylin analog Pramlintide Insulin analogs fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera) Dual PPAR agonists Aleglitazar†, Muraglitazar§, Tesaglitazar§ SGLT2 inhibitor Dapagliflozin†, Remogliflozin† †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.